Pancreatic Cancer Research

Clinical trialPhase 2Completed

Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer

A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer

NCT01231581↗ ClinicalTrials.gov, retrieved 4 November 2026

Outcome
Outcome unknown
Phase
Phase 2
Status
Completed
Study type
Interventional
Start
August 2010
Expected end
February 2013
Enrollment
160 participants
Sites
7
Primary outcomes
Overall Survival
Sponsor
Industry
Results posted
2013-09-26
Last update
26 September 2013

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Papers 1